InvestorsHub Logo
Followers 0
Posts 23
Boards Moderated 0
Alias Born 09/10/2019

Re: runncoach post# 14959

Wednesday, 09/18/2019 2:13:25 PM

Wednesday, September 18, 2019 2:13:25 PM

Post# of 21540
yes both extremes are bad, just the biomarkers or just the clinical diagnosis. Last year, a study came out for nilvapidine. it had prmising potential but it too failed miserably, and without any biomarkers.. Noone has a clue, Did all the patients really have alzheimers? was the dosage adequate or too low? or what went wrong.,

https://www.alzforum.org/news/research-news/nilvadipine-fails-slow-cognitive-decline-ad-patients
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News